Dako to Develop CDx for Merck Cancer Drugs | GenomeWeb

NEW YORK (GenomeWeb News) – Agilent Technologies' Dako business will develop companion diagnostic tests for Merck under a master framework agreement announced today.

The tests will be developed for cancer drugs currently in the pharmaceutical firm's development pipeline. Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.